Apogee Therapeutics had its Relative Strength (RS) Rating upgraded from 61 to 77 Tuesday — a welcome improvement, but still below the 80 or better score you prefer to see.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an 80 or better RS Rating as they begin their largest runs. See if Apogee Therapeutics can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Apogee Therapeutics is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could spark a new run.
The company posted 0% earnings growth in the latest quarterly report. Revenue rose 0%.
The company holds the No. 248 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
